FUKOKU MUTUAL LIFE INSURANCE Co Purchases New Holdings in DexCom, Inc. (NASDAQ:DXCM)

FUKOKU MUTUAL LIFE INSURANCE Co purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,857 shares of the medical device company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. Private Advisor Group LLC increased its position in shares of DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock valued at $759,000 after acquiring an additional 608 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of DexCom during the third quarter valued at approximately $930,000. Hennion & Walsh Asset Management Inc. increased its position in shares of DexCom by 15.1% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock valued at $296,000 after acquiring an additional 579 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of DexCom by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock valued at $3,110,000 after acquiring an additional 3,155 shares during the last quarter. Finally, abrdn plc grew its holdings in DexCom by 28.4% during the third quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock valued at $25,842,000 after purchasing an additional 85,174 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock worth $3,309,794 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on DXCM. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup increased their price objective on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Price Performance

NASDAQ:DXCM opened at $89.91 on Thursday. The firm has a market capitalization of $35.13 billion, a price-to-earnings ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock has a fifty day moving average of $84.29 and a 200 day moving average of $76.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.